ARS Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $32,501 | $15,717 | $7,973 | $86,581 |
Gross Profit | 24,310 | 10,733 | 3,927 | 82,689 |
EBITDA | -48,799 | -44,604 | -36,897 | 47,226 |
EBIT | -51,151 | -44,883 | -37,177 | 47,197 |
Net Income | -51,151 | -44,883 | -33,940 | 49,934 |
Net Change In Cash | 32,501 | 15,717 | 7,973 | 86,581 |
Free Cash Flow | -47,244 | -39,643 | -40,833 | 41,702 |
Cash | 59,557 | 51,540 | 39,864 | 50,817 |
Basic Shares | 98,807 | 98,361 | 98,060 | 97,954 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $89,149 | $30 | $1,316 | $5,506 |
Gross Profit | 68,592 | 30 | 1,316 | 5,293 |
EBITDA | -3,004 | -67,447 | -35,197 | -19,241 |
EBIT | -3,083 | -67,520 | -35,516 | -19,454 |
Net Income | 7,998 | -54,365 | -34,682 | -20,243 |
Net Change In Cash | 89,149 | 30 | 1,316 | 5,506 |
Cost of Revenue | 150,455 | |||
Free Cash Flow | 12,985 | -59,441 | -40,277 | -17,616 |
Cash | 50,817 | 70,971 | 210,518 | 60,063 |
Basic Shares | 102,390 | 95,215 | 39,956 | 28,872 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0 |
2025-09-30 | -$0.52 |
2025-06-30 | -$0.46 |
